• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    57.95 +2.80 (+5.08%)
    Streaming Delayed Price Updated: 11:39 AM EST, Jan 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    34 35 Next >
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗
    There are some risks to consider before jumping on the bandwagon. 
    Via The Motley Fool
    News headline image
    The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
    On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
    Via PredictStreet
    Topics Economy
    Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70% ↗
    Via Stocktwits
    News headline image
    Is CRISPR Therapeutics Stock Yesterday's News? ↗
    The biotech sells blood disorders treatment, Casgevy. 
    Via The Motley Fool
    News headline image
    3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
    All three companies' businesses are on the verge of long-term growth explosions. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗
    Next year could be crucial for the company as sales for its only approved treatment could take off. 
    Via The Motley Fool
    News headline image
    2 Growth Stocks to Invest $1,000 in Right Now ↗
    These stocks have promising assets in their portfolios that could help make their valuations soar in the future. 
    Via The Motley Fool
    News headline image
    From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
    Issued on behalf of Avant Technologies Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    2 Monster Stocks in the Making to Buy and Hold ↗
    The next 12 months will tell us more about their prospects. 
    Via The Motley Fool
    News headline image
    12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗
    The following players span a variety of industries, so if you pick up more than one, you may gain in diversification. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Healthcare Stocks to Buy Ahead of the New Year ↗
    These companies could innovate their way to success. 
    Via The Motley Fool
    News headline image
    2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
    This juicy upside potential comes at a cost. 
    Via The Motley Fool
    News headline image
    Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗
    This company's first product has started to generate revenue. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    The Best Stocks to Buy With $1,000 Right Now ↗
    It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction. 
    Via The Motley Fool
    Topics Artificial Intelligence Energy
    News headline image
    3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗
    These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run. 
    Via The Motley Fool
    News headline image
    Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
    Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
    Via MarketMinute
    News headline image
    Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
    These stocks both have advanced in the double-digits in recent months. 
    Via The Motley Fool
    News headline image
    1 Underrated Stock That Could Soar by 58%, According to Wall Street ↗
    This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy? 
    Via The Motley Fool
    News headline image
    The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
    The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? ↗
    ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
    CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. 
    Via Benzinga
    News headline image
    Why Gene-Editing Giants Crispr And Intellia Just Surged ↗
    The companies are working on one-and-done treatments for diseases tied to genetic problems. 
    Via Investor's Business Daily
    Topics Death
    News headline image
    Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
    The company remains confident in its other gene-editing product, which would treat a swelling disorder. 
    Via Investor's Business Daily
    Topics Death
    News headline image
    AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
    A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
    Via TokenRing AI
    Topics Artificial Intelligence Climate Change Intellectual Property
    News headline image
    Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
    Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam... 
    Via Benzinga
    News headline image
    AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
    The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
    Via TokenRing AI
    Topics Artificial Intelligence
    News headline image
    Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now ↗
    It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
    Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
    Via Benzinga
    News headline image
    2 Soaring Cathie Wood Stocks to Buy and Hold ↗
    These companies' market-beating fuel hasn't run out yet. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    34 35 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.